Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 9.40, representing a potential upside of 27.2% from the current price of HKD 7.39 [3][6]. Core Insights - The company reported a revenue growth of 10.7% year-on-year to RMB 17.57 billion in 1H25, with adjusted net profit increasing by 101.1% to RMB 3.09 billion. The revenue and adjusted net profit for 1H25 accounted for 54.6% and 79.6% of the full-year forecasts, respectively [1][6]. - The revenue from innovative products grew strongly by 27.2% year-on-year to RMB 7.80 billion, representing 44.4% of total revenue, indicating sustained rapid growth in innovative products [1][6]. - The management maintains a full-year guidance for double-digit organic growth based on the rapid growth of innovative products and stable expectations for generic drug business [1][6]. Financial Summary - For FY25E, the company is projected to achieve sales revenue of RMB 34.38 billion, reflecting a year-on-year growth of 19.1% [2][7]. - Adjusted net profit for FY25E is expected to reach RMB 6.27 billion, with a significant growth rate of 81.3% compared to the previous year [2][7]. - The adjusted earnings per share (EPS) for FY25E is forecasted at RMB 0.33, with an adjusted price-to-earnings (P/E) ratio of 20.5 times [2][7]. Pipeline and Market Potential - The company has a rich and differentiated pipeline, with several products showing potential for global top-tier status. The acquisition of Lixin Pharmaceutical has further strengthened its R&D capabilities [6][9]. - Key products such as TQB2868 (PD-1/TGF-β dual antibody) have shown impressive efficacy in clinical trials, with an overall response rate (ORR) of 63.9% in Phase II trials for pancreatic cancer, significantly higher than traditional chemotherapy [6][9]. - The company is expected to announce multiple important clinical data releases in 2H25, which could further enhance its market position [6][9].

Report Industry Investment Rating - Not provided Core Viewpoints - CFAMCI's 1H25 net profit is expected to increase up to 16.3% yoy to RMB6.2bn, with growth mainly due to core business revenue increase, financing cost reduction, and despite asset impairment charges. The higher net profit is expected to boost capital adequacy and lower the leverage ratio. CFAMCIs remain top picks in the Chinese AMC space [7][8][9] - Hongqiao announced a buy - back of 10.2mn shares, which is positive for its CBs and largely neutral for straight bonds. The company maintains a neutral stance on HONGQIs based on valuation [12] Summary by Directory Trading Desk Comments - Asia IG space was unchanged to 3bps tighter yesterday. In Chinese IG, WB 30s tightened by 2bps, TENCNT 38 - 51s/HAOHUA 30/49 were 1bp tighter. Korea IG HYNMTR/LGENSO belly was 1 - 3bps tighter. In financials, HK CHIYBK 32 was 0.4pt higher, JP MUFG 44s were 0.6pt lower. TH banks were unchanged to 2bps tighter. There were small selling on BBLTB 34/40s T2 and better buying on BBLTB senior. STANLN 36s were 2bps wider. In lifers, SHIKON 35 was 1 - 2bp tighter, TYANLI 35 was 0.1pt lower. In HK, CTFSHK 29 was 1.6pt higher, NWDEVL 5.25 Perp/6.25 Perp were 0.3 - 0.4pt higher, HYSAN 4.85 Perp up 0.7pt. In Chinese HY, BTSDF 28 down 0.4pt, WESCHI 26 was 0.1pt lower. In Chinese properties, CHJMAO 29 and CHJMAO Perp were 0.1 - 0.6pt higher, LNGFOR 28/32 were 0.1 - 0.2pt lower, ROADKG 29 - 30 and ROADKG Perps down 0.2pt. In SEA, VLLPM 27 - 29s were 0.2 - 0.9pt higher, VEDLN 29 - 33s were 0.1 - 0.2pt higher, GLPSP Perps down 0.3 - 0.6pt [2] - This morning, the belly of HYNMTR were 2 - 3bps tighter. There were selling in STANLNs, JP lifers/HYSAN/CPREIT. HYSAN 4.85 Perp down 0.7pt, CDBFLC 30 was 1 - 2bps wider, NWDEVL 30 was 0.3pt higher. CFAMCI: 1H25 net profit to increase up to 16.3% yoy to RMB6.2bn, CFAMCI 5.5 47 down 0.5pt this morning while the rest were unchanged. HONGQI: Buy - back of 10.2mn shares, HONGQI 7.05 28 down 0.1pt this morning [3] Top Performers and Underperformers - Top Performers: CTFSHK 4 1/4 06/27/29 up 1.6, TENCNT 3.68 04/22/41 up 1.0, VLLPM 9 3/8 07/29/29 up 0.9, HYSAN 4.85 PERP up 0.7, CHJMAO 4 1/4 07/23/29 up 0.6 [4] - Top Underperformers: GARUDA 6 1/2 12/28/31 down 1.4, TSIVMG 1.55 12/17/29 down 1.0, TAISEM 3 1/8 10/25/41 down 0.6, GLPSP 4.6 PERP down 0.6, MUFG 4.7 03/10/44 down 0.6 [4] Macro News Recap - Macro: S&P (-0.01%), Dow (-0.08%), and Nasdaq (+0.03%) were mixed on Monday. UST yield was higher, with 2/5/10/30 yield at 3.77%/3.86%/4.34%/4.94% [6] Desk Analyst Comments - CFAMCI's 1H25 net profit growth is due to core business revenue increase, financing cost reduction, and despite asset impairment charges. The company's focus on high - quality investments and diverse funding channels support profit growth, and the higher net profit is expected to boost capital adequacy and lower the leverage ratio [7][8] - The company maintains a buy on CCAMCL 4.4 Perp and a neutral stance on GRWALL 7.15 Perp. It prefers CFAMCI 3.875 11/13/29, CFAMCI 3.375 02/24/30, and CFAMCI 3.625 09/30/30 within the CFAMCI curve [9] Hongqiao Analysis - Hongqiao announced a buy - back of 10.2mn shares for cHKD234mn, with a latest mandate of no less than HKD3bn. The buy - back aims to minimize dilution as its o/s USD300mn CB due Jan'26 will be converted into shares. It is positive for CBs and largely neutral for straight bonds. The company maintains a neutral stance on HONGQIs [12] Offshore Asia New Issues - Priced: DBS Bank issued USD2000mn with a 3 - year tenor at 3.989%, Zhangzhou Yuanshan Development issued USD22mn with a 3 - year tenor at 7.0% [13] - Pipeline: Ganzhou Urban Investment Holding plans a 3 - year issue at 5.4%, Tongling State - owned Capital Operation Holding Group plans a 3 - year issue at 5.1% [14] News and Market Color - Onshore primary issuances: 97 credit bonds were issued yesterday with an amount of RMB69bn. Month - to - date, 1,208 credit bonds were issued with a total amount of RMB1,081bn, a 0.2% yoy decrease - Other news: COGARD extended RSA fee deadlines, FUTLAN/FTLNHD obtained bourse approval for onshore ABS offering, HYSAN completed the redemption of USD850mn HYSAN 4.1 Perp, HYUELE repaid KRW3.4tn loans, LGELEC started a voluntary retirement program [15] - Other corporate news: NIO to expand into Singapore, Uzbekistan, and Costa Rica; PTTGC eyes THB30bn from non - core assets monetization; Rakuten to start satellite - based services; Road King's loss to widen; SoftBank to acquire a stake in Intel; Tongyang Life to redeem USD300mn TYANLI 5.25 Perp; Vedanta Ltd to consider second interim dividend; Hindustan Zinc to set up a tailings reprocessing plant [21]

Global Market Overview - The Hang Seng Index closed at 25,177, down 0.37% for the day but up 25.51% year-to-date [1] - The S&P 500 closed at 6,449, down 0.01% for the day and up 9.65% year-to-date [1] - The Shanghai Composite Index rose by 0.85% to 3,728, with a year-to-date increase of 11.23% [1] Industry Insights - The healthcare sector showed resilience, with major life sciences companies reporting better-than-expected performance in 2Q25, leading to upward revisions in annual guidance [5][6] - The pharmaceutical industry is facing pressure on profit margins due to external factors, but major pharmaceutical companies continue to invest in R&D, indicating a stable outlook for innovation [8] - The retail sector in the U.S. demonstrated resilience with a monthly growth rate increase from 0% in the first half of the year to 0.7% in July, indicating strong consumer spending [4] Company Analysis - Tongcheng Travel reported a total revenue of RMB 4.7 billion in 2Q25, a 10% year-on-year increase, with adjusted net profit rising by 18% to RMB 775 million, exceeding expectations [8] - Xtep's sales for the first half of 2025 grew by 7% to RMB 6.8 billion, with net profit increasing by 21% to RMB 913 million, surpassing forecasts [13] - Leap Motor achieved a revenue of RMB 14.2 billion in 2Q25, a 42% quarter-on-quarter increase, marking its first positive operating profit [14] Investment Ratings - Leap Motor is rated as a "Buy" with a target price of HKD 80, reflecting a strong growth outlook driven by new model launches and expanding sales [14] - Xtep maintains a "Buy" rating with a target price of HKD 7.39, supported by robust sales performance and operational efficiency [12] - Tongcheng Travel is also rated as a "Buy," with a target price of HKD 24.00, based on its strong core business performance [8]

Group 1: Stock Recommendations - Geely Automobile is rated as a "Buy" with a target price of HKD 25.00, representing a potential upside of 25%[5] - Li Auto is rated as a "Buy" with a target price of HKD 72.00, indicating a potential upside of 7%[5] - Sany International is rated as a "Buy" with a target price of HKD 8.70, suggesting a potential upside of 22%[5] - Luckin Coffee is rated as a "Buy" with a target price of USD 44.95, indicating a potential upside of 17%[5] - Tencent is rated as a "Buy" with a target price of HKD 705.00, representing a potential upside of 19%[5] Group 2: Performance Overview - The basket of 26 long positions had an average return of 4.7%, compared to the MSCI China Index return of 5.2%[10] - Out of the 26 stocks, 11 stocks outperformed the benchmark[10] - The report includes a total of 26 stocks with varying sectors such as automotive, technology, and healthcare[5]

Investment Rating - The report assigns a "Buy" rating to Thermo Fisher, while other companies such as Danaher, Samsung Bio, and Lonza remain unrated [2]. Core Insights - The report highlights that the impact of tariffs on the life sciences upstream sector is less than expected, leading to an overall upward revision of performance guidance for 2025 by most companies [4][29]. - Clinical CRO orders have unexpectedly increased, driven by strong biotech client demand, although the sustainability of this trend remains uncertain [4][31]. - The revenue recovery is outpacing profit recovery, with cost control pressures increasing due to external macroeconomic challenges [6][14]. Summary by Sections Performance Analysis - In 1H25, the performance of overseas CXO and life sciences upstream companies remained under pressure, but a sequential improvement was observed in 2Q25, with 7 out of 10 tracked companies showing revenue growth compared to 1Q25 [6][31]. - The median and average revenue growth rates for 2Q25 were +4.3% and +7.1%, respectively, compared to +0.2% and +6.0% in 1Q25, primarily driven by clinical CRO companies [6][8]. Tariff Impact - The impact of tariffs on sales of instruments and equipment for drug development and production was reported to be less than anticipated, with management from major life sciences companies indicating a more favorable outlook [29][30]. - Companies like Thermo Fisher and Danaher have adjusted their performance guidance upwards, reflecting a more optimistic view on tariff impacts [29][30]. Demand Trends - The C(D)MO sector continues to see strong commercial production demand, while life sciences upstream companies benefit from a recovery in consumable demand as clients complete inventory destocking [31][32]. - Clinical CRO demand has been bolstered by unexpected growth from biotech clients, although the sustainability of this demand is still in question [33][34]. Financial Metrics - The average gross margin for heavy asset companies decreased from 50.2% in 2021 to 45.7% in 2024, but showed signs of recovery in 2Q25 [15]. - The report notes that capital expenditures are expected to reverse the declining trend observed in 2023-24, potentially increasing future depreciation pressures [17]. Market Reactions - Following the release of 2Q25 results, stock prices for most overseas CXO and life sciences companies reacted positively, particularly for clinical CROs, which saw significant price increases due to better-than-expected performance [24][25].

Market Overview - Global markets showed mixed performance, with the Hang Seng Index declining by 0.98% while the Shanghai Composite Index increased by 0.83% [1][3] - Southbound capital inflow reached a record high of HKD 35.876 billion, indicating strong interest in Hong Kong stocks [3] Sector Performance - The Hong Kong stock market experienced a pullback, particularly in consumer discretionary, essential consumer goods, and real estate sectors, while materials, healthcare, and industrial sectors saw gains [3] - The Hang Seng Financial Index fell by 1.25%, and the Hang Seng Real Estate Index dropped by 1.83% [2] Company Insights - NetEase Cloud Music reported a 6% decline in total revenue to RMB 3.83 billion for 1H25, but adjusted operating profit increased by 35% to RMB 905 million, driven by improved commercialization and cost control [4] - Weibo's 2Q25 revenue grew by 2% to USD 444.8 million, exceeding expectations, but the outlook for 2H25 remains uncertain due to challenges in the advertising business [5] - China Hongqiao's net profit for 1H25 was RMB 12.3 billion, a 35% increase, and the company announced a new share buyback plan to enhance market confidence [5] - China Lilang's sales for 1H25 increased by 8% to RMB 1.73 billion, but net profit fell by 14% to RMB 181 million, attributed to rising operational costs [9] Investment Ratings - NetEase Cloud Music maintained a "Buy" rating with a target price of HKD 330, reflecting an upward revision based on operational efficiency improvements [4] - Weibo also holds a "Buy" rating with a target price of USD 14.5, despite a slight downward adjustment in revenue forecasts [5] - China Hongqiao is rated "Buy" with a target price raised to HKD 27, supported by strong profit growth and a favorable industry outlook [5] - China Lilang's target price was lowered to HKD 4.42, but it retains a "Buy" rating due to attractive dividend yields [8]

Retail Performance - In July, U.S. retail and food service sales increased by 0.5% month-on-month, slightly below the market expectation of 0.6%[5] - The average monthly growth rate of retail sales rose from 0% in January-May to 0.7% in June-July, indicating a recovery in consumer demand[2] - Automotive sales rebounded, with a month-on-month growth rate increasing from 1.4% in June to 1.6% in July after a cumulative decline of 4.6% in the first five months of 2023[5] Industrial Output - Industrial production fell by 0.1% month-on-month in July, primarily due to declines in mining and utilities, which dropped to -0.4% and -0.2% respectively[5] - Manufacturing output remained flat at 0% month-on-month, with significant increases in medical equipment (2.6%) and semiconductors (2.9%), while apparel and automotive sectors saw declines[5] Economic Outlook - Federal Reserve Chair Jerome Powell's upcoming speech at Jackson Hole is expected to defend the independence of the central bank and reduce market expectations for significant interest rate cuts[2] - With inflation expected to rebound and unemployment rates remaining low, the Federal Reserve is anticipated to keep interest rates unchanged in September, followed by rate cuts in October and December[2]

Group 1: Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 25,519, down 0.37% for the day but up 27.22% year-to-date [1] - European markets continued to rise for the third consecutive day, with the UK stock market reaching a historical high [3] - US markets exhibited mixed results, with financials, healthcare, and consumer discretionary sectors leading gains, while industrials and materials lagged [3] Group 2: Company Analysis - JD.com - JD.com reported Q2 2025 revenue of 356.7 billion RMB, a 22.4% year-on-year increase, exceeding market expectations by 6% [4] - Non-GAAP net profit fell 49% year-on-year to 7.4 billion RMB due to increased investment in the food delivery business, but was 38% higher than market expectations [4] - The management emphasized strong early synergies between the e-commerce and food delivery businesses, with active user growth exceeding 40% year-on-year [4] Group 3: Company Analysis - NetEase - NetEase's Q2 2025 revenue grew 9% year-on-year to 27.9 billion RMB, slightly below market expectations [4] - Non-GAAP net profit increased by 22% to 9.5 billion RMB, aligning with market expectations [4] - The company anticipates resilient growth in gaming revenue for the second half of 2025, driven by strong performance in evergreen games [4] Group 4: Company Analysis - Geely Automobile - Geely's Q2 2025 revenue met expectations, with a gross margin improvement of 1.3 percentage points to 17.1%, exceeding market forecasts [5][6] - The company plans to launch five new electric vehicle models in the second half of the year, targeting competitive pricing in underrepresented market segments [6] - Adjusted profit forecasts for 2025 have been slightly increased to 17.7 billion RMB, reflecting improved synergy from brand integration [6] Group 5: Company Analysis - Jizhi Technology - Jizhi Technology is positioned as a new star in the global warehouse automation market, with over 800 end customers across 40 countries [7] - The company is expected to achieve a compound annual growth rate of 34% in revenue from 2024 to 2027, with meaningful profitability anticipated starting in 2026 [7] - As the first AMR company listed in Hong Kong, Jizhi Technology holds a unique market position [7] Group 6: Investment Ratings - Geely Automobile is rated "Buy" with a target price of 25 HKD, reflecting a 27% upside potential [8] - JD.com is rated "Buy" with a target price of 49.4 USD, indicating a strong outlook despite short-term profit pressures [4][8] - NetEase is rated "Buy" with a target price of 160.0 USD, supported by positive gaming revenue forecasts [4][8]

Investment Rating - The report initiates coverage on Geekplus (2590 HK) with a "Buy" rating and a target price of HKD 26.7, representing a potential upside of 42.3% from the current price of HKD 18.76 [1][3]. Core Insights - Geekplus is positioned as a rising star in the global AMR (Autonomous Mobile Robot) market for warehouse automation, with a unique presence in the Hong Kong market. The company has over 800 end customers across 40 countries, with an expected overseas revenue contribution of 72% in 2024 [1]. - The AMR solutions market is projected to grow significantly, with the market size expected to increase from RMB 39 billion in 2024 to RMB 162 billion by 2029, driven by an increase in AMR penetration from 8% to 20% of total warehouse automation solutions revenue [7]. - Geekplus holds a 9% market share in warehouse fulfillment revenue, ranking first globally, attributed to its modular design solutions that integrate easily into existing customer systems, minimizing operational disruptions [7]. - The report highlights the cost-saving and efficiency improvements experienced by Geekplus customers, exemplified by YesAsia, which saved approximately USD 10 million in costs and improved order accuracy to 99.99% after implementing Geekplus AMR solutions [7]. Financial Summary - The forecasted revenue for Geekplus is expected to grow from RMB 2,143 million in FY23A to RMB 5,788 million by FY27E, reflecting a compound annual growth rate (CAGR) of 34% from 2024 to 2027 [2][8]. - Adjusted net profit is projected to turn positive starting in FY26E, with estimates of RMB 112 million in FY25E and RMB 673.5 million in FY27E [2][8]. - The company is expected to achieve a gross margin improvement from 17.7% in FY22A to 39.0% by FY27E, indicating enhanced profitability [9].

Report Industry Investment Rating - Not provided in the given content Core Viewpoints - After the release of US CPI data, Asia IG opened firmly, and the market almost fully priced in a 25bps rate cut in Sep'25 and a high chance of another 25bps cut in Oct'25 [1] - CMBI expects USD/RMB may drop again in 4Q25 when US inflation might decline and China might launch additional fiscal stimulus; USD/RMB to reach 7.10 at end - 2025 [2] - Maintain buy on INDYIJ 8.75 05/07/29, considering its sufficient liquidity, disciplined capex, and strong technicals in the Indonesia oil & gas and mining sectors [13] - The PBOC will maintain easing liquidity condition, which is positive for Chinese stocks and commodities, and might cut RRR by 50bps and LPRs by 10bps in 4Q25 [17] Summary by Relevant Catalogs Trading Desk Comments - Asia IG opened firmly after US CPI data release. Newly issued WYNMAC 6.75 moved 0.7pt higher, and some bonds like MGMCHIs, MTRC perps, etc., had price changes. Chinese properties ROADKG 28 - 30s dropped 2.3 - 3.3pts [1] - SHIKON tightened 5bps in the morning, HK banks T2s tightened 3bps, Korea space was unchanged to 2bps tighter, and some floaters and perps had price movements [2] - There is demand from China - based investors for Japanese insurance hybrids and Yankee AT1s, and bonds in SEA and LGFV also had price changes [3] Marco News Recap - On Wednesday, S&P (+0.32%), Dow (+1.04%), and Nasdaq (+0.14%) were higher, and UST yield was lower with 2/5/10/30 yield at 3.67%/3.77%/4.24%/4.83% [6] Desk Analyst Comments - INDYIJ's 1H25 profit eroded due to lower ASP and softened market demand. Revenue declined 20.0% yoy to USD957mn, with coal ASP and sales volume decreasing. Operating profit and adj. EBITDA dropped 49.4% and 28.1% respectively [7] - Indika has been diversifying into non - coal businesses, but coal operations still drive performance. It incurred negative FCF in 1H25, and total debt/LTM EBITDA and net debt/LTM EBITDA weakened [9][10][11] - Indika has proactive liability management and smooth access to funding channels. The company is considered a candidate for early redemptions, and INDYIJ 8.75 05/07/29 is recommended as a good carry play [12][13] China Economy - Social financing extended recovery due to robust government bond issuance, but private - sector Renminbi loans slowed. The PBOC will maintain easing liquidity to stimulate credit demand [17] - The central bank might cut RRR by 50bps and LPRs by 10bps in 4Q25. US$/RMB may rise in Aug - Sep and drop in 4Q25, reaching 7.10 at end - 2025 [17] - Outstanding social financing edged up to 9% in July, SF flow expanded by 50.5% but fell short of expectation. Government and corporate bond issuances were strong, while RMB loans to the real economy dropped [18] - New RMB loans remained subdued, with growth of outstanding RMB loans edging down to 6.9% in July. Credit demand in household and corporate sectors was weak, and bill financing increased [19] Offshore Asia New Issues - New issues include Chengdu Sino French Ecological (USD100mn, 3yr, 6.8%) and Henan Water Conservancy Investment (USD500mn, 3yr, 4.3%) [22] - There is no offshore Asia new issues pipeline today [23] News and Market Color - There were 94 credit bonds issued onshore yesterday with an amount of RMB70bn, and 930 credit bonds issued month - to - date with a 9.5% yoy increase [24] - Various companies had news such as Adani solar arm sued, Adani Ports accepting tendered bonds, Azure Power seeking debt, etc. [24]